Regulation
Patient enrolment concludes in Glaukos’ Preserflo MicroShunt trial
Glaukos has completed patient enrolment in its US 510(k) pivotal trial for the Preserflo MicroShunt, a drainage device designed to treat primary open-angle glaucoma in adults. The trial conclusion marks a milestone toward potential FDA clearance of the device.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network